-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 13, Cansino announced that the 13-valent pneumococcal polysaccharide conjugate vaccine developed by the company has completed preparations for phase III clinical trials and officially entered phase III clinical trials.
Pneumococcal disease is one of the serious public health problems in the world.
The main pathogens of serious diseases such as inflammation, meningitis, and bacteremia are also common causes of acute otitis media and sinusitis .
In developed countries and regions, the introduction and widespread use of pneumococcal polysaccharide conjugate vaccines have effectively controlled serious diseases caused by Streptococcus pneumoniae.
However, in Africa and Asia, the number and proportion of children under 5 years of age are still relatively high.
WHO recommends that countries around the world should the pneumococcal polysaccharide conjugate vaccine into this child immunization programs of countries, especially in countries with high child mortality should introduce multi-antigen polysaccharide pneumococcal conjugate vaccine in national immunization programs as a high-priority project.
In the "Global Action Plan for the Prevention and Control of Pneumonia " (GAPP), WHO puts forward the goal of "eliminating preventable pneumonia-induced deaths in children by 2025".
The introduction of pneumococcal polysaccharide conjugate vaccine is the main means to achieve this goal.
